NantOmics specializes in precision medicine by providing advanced molecular testing solutions that assess genomic and proteomic alterations in cancer. The company employs an integrated panomic approach, which combines whole genome sequencing, RNA sequencing, and quantitative proteomics to create a comprehensive molecular profile of a patient's tumor. This methodology allows for the identification of tumor-specific alterations at the DNA level, while RNA sequencing helps confirm the relevance of these mutations. Additionally, quantitative proteomics measures clinically significant protein levels, and integrative analysis identifies disrupted pathways unique to the patient's cancer, facilitating personalized treatment options.

The proprietary analytical platform developed by NantOmics enhances molecular diagnostic capabilities, delivering actionable intelligence and decision support for healthcare providers at the point of care. Their extensive knowledge database, which includes numerous oncogenes and cellular pathways, plays a crucial role in matching identified genomic and proteomic alterations to targeted therapies. This approach not only aids in the personalized management of cancer patients but also ensures that treatment options are tailored to the specific molecular characteristics of each individual's tumor.

United States

NantOmics employs a comprehensive, integrated panomic approach to detect molecular alterations in individual tumors and inform personalized treatment options for patients with cancer. Whole genome sequencing of a patient’s matched tumor sample and normal sample pinpoints tumor-specific alterations at the DNA level, RNA sequencing confirms and gives relevance to mutations in DNA, quantitative proteomics measures the levels of clinically important proteins, and integrative analysis identifies disrupted pathways that are specific to the patient’s tumor.

NantOmics

Company Details